Program
SHR-2017
A development code. Also written as “SHR-2017 injection”.
In Jiangsu HengRui Medicine's pipeline, RANKL/ NGF
. Its studies are mostly in Neoplasm Metastasis · Osteoporosis, led by Jiangsu HengRui Medicine.
Furthest: phase 1, since Jun 26, 20232 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 21 open or running | phase 1since Jun 26, 2023 | Jun 26, 2023 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-2017
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2023First study: phase 1 study in OsteoporosisFirst studyNCT05930704 · 45 planned · China
- Apr 18, 2024Phase 1 study in Patients With Bone MetastasesNCT06380881 · 25 enrolled · China
TargetBeta
“RANKL/ NGF”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06380881Patients With Bone Metastases · China | 1 | Completed | Aug 6, 2025 | 25 |
| NCT05930704Osteoporosis · China | 1 | Recruiting | Apr 12, 2025 | 45 |
How it is read
Names in the registry
- “SHR-2017”, 1 entry
- “SHR-2017 injection”, 1 entry
Codes read as this program: SHR2017.
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
- Osteoporosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.